Use of heterocyclic compounds as SCCE inhibitors
US7872052B2 · kind B2 · utility
16Cited by
3References
24Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 7, 2004 |
| Grant date | Jan 18, 2011 |
| Priority date | — |
| Expiry date | Mar 4, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to heterocyclic inhibitors of stratum corneum chymotryptic enzyme (SCCE). More particularly, the invention relates to the use of compounds with the formula (I) or (II) for treatment of certain diseases, in particular skin diseases such as pruritus, as well as cancer such as ovarian cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.